Scientific Reports (Nov 2023)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia

  • Hong Chang,
  • Guangsheng He,
  • Rong Fu,
  • Fei Li,
  • Bing Han,
  • Tao Li,
  • Lei Liu,
  • Hemant Mittal,
  • Hantao Jin,
  • Fengkui Zhang

DOI
https://doi.org/10.1038/s41598-023-45607-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

Abstract For patients with severe aplastic anemia (SAA) in China who have had an insufficient response to the first-line treatment with hematopoietic stem cell transplantation or immunosuppressive therapy, there is no established standard of care other than transfusion support and treatment of infections. This non-randomized, open-label, Phase II multicenter trial investigated the efficacy and safety of eltrombopag in 20 adult Chinese patients with refractory or relapsed (r/r) SAA. The primary endpoint of hematologic response rate at Week 26, defined as the proportion of patients who met any of the International Working Group criteria, was observed in 70% (14/20) of patients, with more than 50% of these having at least bi-lineage response. Reduced red blood cell and platelet transfusion at Week 26 were observed in 57% (8/14) and 80% (8/10) of patients, respectively. Safety findings were consistent with the established safety profile of eltrombopag and no new safety signals were reported. None of the patients discontinued eltrombopag because of safety concerns. Although the sample size was small, this is the first prospective study to show that eltrombopag is efficacious and has a favorable safety profile in a Chinese patient population with r/r SAA. Trial registration: This trial is registered on ClinicalTrials.gov (NCT03988608); registered 17 June 2019.